Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Galapagos NV ADR (NQ: GLPG )

27.29 +0.07 (+0.26%)
Streaming Delayed Price Updated: 3:30 PM EDT, Jul 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 65,607
Open 26.95
Bid (Size) 27.26 (1)
Ask (Size) 27.32 (3)
Prev. Close 27.22
Today's Range 26.94 - 27.63
52wk Range 24.78 - 44.25
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
GLPG Stock Earnings: Galapagos Beats EPS, Misses Revenue for Q1 2024
GLPG stock results show that Galapagos beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell... 
Via Newsfile

Performance

YTD
-33.99%
-33.99%
1 Month
+4.24%
+4.24%
3 Month
-5.14%
-5.14%
6 Month
-28.71%
-28.71%
1 Year
-33.71%
-33.71%

More News

Read More
Galapagos Downgraded, Pharma Firm Faces Uphill Battle With Slow Pipeline Progress: Analyst
Via Benzinga
Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline
From Frontier Medicines
Via GlobeNewswire
8 Analysts Have This to Say About Galapagos
Via Benzinga
Where Galapagos Stands With Analysts
Via Benzinga
JP Morgan Maintains Neutral Rating for Galapagos: Here's What You Need To Know
Via Benzinga
Earnings Outlook For Galapagos
Via Benzinga
European Drugmaker Galapagos Collaborates With Biotech BridGene Biosciences To Develop Cancer Treatments
Via Benzinga
GLPG Stock Earnings: Galapagos Beats EPS, Beats Revenue for Q3 2023
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For May 8, 2023
Via Benzinga
BigCommerce, ContextLogic And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Earnings Preview For Galapagos
Via Benzinga
Where Galapagos Stands With Analysts
Via Benzinga
Galapagos' Blood Cancer Candidate Shows 100% Objective Response Rate In Relapsed/Refractory Patients
Via Benzinga
Why Galapagos Stock Is Falling Today
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 23, 2023
Via Benzinga
Where Galapagos Stands With Analysts
Via Benzinga
Twitter Rolls Out 'Blue For Business,' Visa Pitches Auto-Payments On Ethereum Blockchain, Justin Bieber Slams H&M: Today's Top Stories
Via Benzinga
On A Mission As Top European Player, Galapagos Looks For Acquisition Targets
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 7, 2022
Via Benzinga
After FDA, European Agency Limits Use Of Certain JAK Inhibitors Amid Safety Concerns
Via Benzinga
Expert Ratings for Galapagos
Via Benzinga
3 Biotech Stocks to Sell in October
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.